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Abstract: Human papillomavirus type 16 (HPV16) causes a range of cancers including cervical
and head and neck cancers. HPV E6 oncoprotein binds the cell polarity regulator hDlg (human
homologue of Drosophila Discs Large). Previously we showed in vitro, and now in vivo, that hDlg also
binds Connexin 43 (Cx43), a major component of gap junctions that mediate intercellular transfer of
small molecules. In HPV16-positive non-tumour cervical epithelial cells (W12G) Cx43 localised to
the plasma membrane, while in W12T tumour cells derived from these, it relocated with hDlg into
the cytoplasm. We now provide evidence that E6 regulates this cytoplasmic pool of Cx43. E6 siRNA
depletion in W12T cells resulted in restoration of Cx43 and hDlg trafficking to the cell membrane.
In C33a HPV-negative cervical tumour cells expressing HPV16 or 18 E6, Cx43 was located primarily
in the cytoplasm, but mutation of the 18E6 C-terminal hDlg binding motif resulted in redistribution
of Cx43 to the membrane. The data indicate for the first time that increased cytoplasmic E6 levels
associated with malignant progression alter Cx43 trafficking and recycling to the membrane and the
E6/hDlg interaction may be involved. This suggests a novel E6-associated mechanism for changes
in Cx43 trafficking in cervical tumour cells.
Keywords: human papillomavirus (HPV); E6 oncoprotein; Connexin 43 (Cx43) trafficking;
human homologue of Drosophila discs large (hDlg)
1. Introduction
Gap junctions are specialized cell membrane channels that allow direct intercellular diffusion
of critical regulatory ions and small molecules between contiguous cells and are normally present in
large aggregates called “plaques” on the cell membrane [1,2]. Gap junction assembly is dependent on
the efficient delivery of connexons (half of a gap junction) to the plasma membrane and subsequent
docking of these between adjacent cells [3]. Gap junctions are then recycled from the centre of the
plaques into the endosomal/lysosomal pathway, but they can also be degraded by the proteasome [4].
Regulation of gap junctional intercellular communication (GJIC) has been demonstrated to produce
cellular changes underlying tumour formation. Additionally, connexons have been shown to have
gap junction-independent tumour promoting activity [5].
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There are 21 human connexin proteins, all of which have four transmembrane α helices anchored
in the cell membrane with a short N- and variable length C-terminus in the cytoplasm [3]. For
example, Connexin 43 (Cx43), the most widespread connexin and a major component of gap junctions
in stratified epithelia, has a 151 amino acid long C-terminus which integrates with intracellular
signalling pathways [6]. A body of evidence has accumulated to show that GJIC may be lost during
malignant progression, as seen in HPV-positive cervical cancer [7]. Cx43 is often down-regulated in
epithelial carcinomas [7] as well as precancerous lesions [8] although in other cases expression may be
increased in invasive tumours [9]. Nevertheless, the steps leading to changes in connexin expression
and trafficking and how these are related to tumour progression are largely unknown.
Human papillomaviruses (HPVs) are small double-stranded DNA viruses, which infect the
stratified epithelia [10]. HPV16 is the most prevalent so-called “high-risk” HPV genotype associated
with cervical and other anogenital carcinomas [11], in addition to a subset of head and neck
cancers [12]. Progression from the premalignant to malignant phase of high-risk HPV-associated
disease is driven by overexpression of the viral oncoproteins E6 and E7 [10]. In the nucleus, E6
binds and targets the tumour suppressor p53 for degradation [13]. However, E6 also contains
a highly conserved C-terminal motif [14,15] that can interact with the PDZ (PSD-95/Dlg/ZO-1)
domain-containing proteins MAGI-1, 2, 3, MUPP-1, hScrib and hDlg [16,17]. In vitro and in vivo
studies have revealed that the E6 PDZ binding motif is essential for the HPV infectious life
cycle and for HPV-associated tumour progression underlining the importance of E6/PDZ protein
interactions [15,18].
Proteins of the membrane-associated guanylate kinase homologue (MAGUK) family can form
protein scaffolds and comprise macromolecular complexes with protein partners thought to be
involved in cell signalling cascades and cell morphology organization [19,20]. hDlg is a MAGUK
protein located at intercellular contact sites in epithelial cells [21,22]. Previously we reported an
interaction between Cx43 and hDlg in HPV16-positive cervical epithelial cells. The C-terminal
domain of Cx43 binds the N- and C-termini of hDlg [23]. hDlg and Cx43 were both located
at the plasma membrane in non-tumour cervical epithelial cells (W12G) but were co-localised
in the cytoplasm in invasive cervical tumour cells derived from these (W12T; formerly named
W12GPXY) [23,24]. Functional studies indicated that hDlg was responsible for maintaining a
cytoplasmic pool of Cx43, protected from degradation that may be capable of trafficking to
the membrane.
In this study we first demonstrate a physical association between hDlg and Cx43 in vivo. The
known interaction of E6 with hDlg prompted us to investigate whether HPV16 E6 could interact with
and regulate the subcellular location of the hDlg/Cx43 complex. We detected association of E6 with
Cx43 at low levels in W12T cells. However, E6 siRNA depletion in W12T cells caused redistribution
of Cx43 from the cytoplasm to the membrane. Conversely, overexpression of HPV 16 or 18 E6 in
HPV-negative C33a cells resulted in reduced levels of Cx43 and redistribution from the membrane
to the cytoplasm. Finally, HPV-negative C33a cells overexpressing a wild type or mutant HPV18
E6 demonstrated the critical role E6 plays in membrane localisation of Cx43. These findings reveal
a novel E6-regulated pathway through which Cx43 trafficking, and potentially GJIC, is altered in
cervical tumour cells.
2. Materials and Methods
2.1. Cell Culture and Antibodies
W12G cells are non-tumour cervical epithelial cells (clone 20861: [25]). W12T cells are invasive
tumour cells derived from W12G cells. They were originally called W12GPXY [24]. W12T, C33a, and
HEK-293 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% FCS; W12E, W12G cells were cultured in serum-free keratinocyte growth medium (KGM) from
Cambrex, UK (cc-3101). All cells were maintained under humidified 5% CO2 at 37 ˝C.
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Polyclonal antibody raised in rabbits against a synthetic peptide corresponding to residues
363–382 of native Cx43, was kindly provided by Dr E. Rivedal, The Norwegian Radium Hospital,
Oslo. Polyclonal antibodies against HPV-16 E6 (sc-1583) and against ZO-1 (61-7300) and a
monoclonal antibody against hDlg (sc-9961) were purchased from Santa Cruz Biotechnology,
California, CA, USA. Polyclonal antibody against flag (F7425) was purchased from Sigma (Poole, UK).
Monoclonal antibody against Cx43 (C-6219) was purchased from Sigma. Antibody dilutions were as
described [23].
2.2. Proximity Ligation Assay (PLA)
Archival paraffin-embedded cervical biopsy samples were obtained with ethical permission
(Glasgow Royal Infirmary: RN04PC003). Diagnosis was made by two gynaehistopatholgists.
HPV presence was confirmed by PCR. Sections on slides were de-paraffined, and antigen retrieval
performed using sodium citrate (10 mM, pH6.0). Sections were incubated in blocking solution (PBS,
0.5% BSA, 0.25% TritonX-100) for 1 h and primary antibodies for Cx43 (Rivedal, 1:50) and hDlg
(Santa Cruz, 1:50) added in blocking solution overnight at 4 ˝C. For standard immunofluorescence,
samples were washed in PBS three times, blocked for 30 min, then secondary antibodies (Alexa Fluor,
Lifetechnologies, Paisley, UK, 1:500) added for 30 min at room temperature. For Proximity Ligation
Assay (PLA), following overnight primary antibody incubation, samples were washed in PBS and
detection performed using a Duolink kit (Sigma, Poole, UK) as previously described [26]. All samples
were mounted using ProLong antifade diamond containing DAPI (Life Techologies, Paisley, UK).
Negative controls (no primary antibody) were included in all experiments. Images were taken using
a Zeiss LSM510 Meta confocal microscope.
2.3. Co-Immunoprecipitation
Cells at 70% confluence were washed twice with ice-cold PBS and scraped into 5 mL chilled IP
buffer containing PBS, 1% Triton X-100, 0.5% CHAPS, 0.1% SDS with one tablet of mini-proteinase
inhibitor cocktail and one tablet of PhosSTOP phosphatase inhibitor cocktail per 10 mL (Roche, UK).
The cell lysates were incubated on ice for 15 min and the solutions sonicated for 1 min on ice. Cell
lysates were then cleared of cellular debris by centrifugation at 12,000 g for 10 min at 4 ˝C and
the protein concentration determined by Bradford’s assay (Bio-Rad Laboratories, Hemel Hempstead,
UK). Cell lysates were pre-cleared with protein-G sepharose beads (Sigma, Poole, UK) for one hour
at 4 ˝C. Primary antibodies were then added to 100 µg protein of each cell lysate and incubated
for 2 h at 4 ˝C with rotation. Subsequently, 40 µg of reconstituted protein G-Sepharose was added
and the volume was adjusted to 750 µL.The samples were mixed by rotation at 4 ˝C for 4–5 h.
Immunocomplexes were then harvested by centrifugation and washed four times with 250 µL
ice-cold IP buffer and once with 25 µL ice cold PBS. Proteins were solubilised by sonicating the
complexes in PBS mixed with 5 µL 6ˆ protein loading buffer (1ˆ buffer: 125 mM Tris (pH 6.8),
4% SDS, 20% glycerol, 10% mercaptoethanol and 0.006% bromophenol blue) for 5 min on ice and
separated by SDS-PAGE.
2.4. Western Blotting
Confluent cells were scraped into protein-loading buffer (125 mM Tris (pH 6.8), 4% SDS,
20% glycerol, 10% mercaptoethanol and 0.006% bromophenol blue, fresh protein inhibitor cocktail
(Roche, Welwyn Garden City, UK); 50 µg protein was resolved by polyacrylamide gel electrophoresis
and subsequently transferred to a nitrocellulose membrane. The membrane was preincubated for 1 h
at room temperature with 5% dried milk in PBS-0.1% Tween, before overnight incubation at 4 ˝C with
diluted primary antibody in PBS-Tween, 1% dried milk. Horseradish peroxidase (HRP)-conjugated
secondary antibodies were diluted 1:1000 in PBS-Tween and incubated for 1 h. The blot was
developed using Pierce enhanced chemi-luminescence (ECL) kit and exposed to Kodak X-OMAT film.
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2.5. Plasmid Construction and Cell Transfection
The HPV18 E6 wild type gene and E6 aa156 ThrÑ Glu mutation cloned into pcDNA-3 plasmid
were provided by Dr Lawrence Banks [27]. The plasmids were sequentially digested with EcoR I
and Hind III, then the E6 fragments were purified with phenol:chloroform extraction and ethanol
precipitation. The vector p3x-FLAG-CMVTM-10 (Sigma, Poole, UK) was cut with EcoR I and Hind III
and ligated with the wild type and mutant HPV18 E6 DNA fragments to generate the pN-terminus
3XFLAG-fused wild-type HPV18 E6 (pNFWE6) and pN-terminus 3X FLAG-fused mutant HPV 18 E6
(pNFME6). The recombined plasmids were sequenced to confirm correct insertion.
C33a cells (2 ˆ 105) were transfected with 3 µg of p3x-FLAG-CMVTM-10, pNFWE6 or pNFME6
using Lipofectamine (Invitrogen, Paisley, UK) according to the recommended protocol and selected
in medium supplemented with 500 µg/mL G418 (Sigma, Poole, UK) to obtain stably transfected
cell colonies. The experiments were carried out with 2 independent cell lines selected from each
transfection. The plasmid pMAXGFP was used as an expression control plasmid and for calculating
transfection efficiency.
2.6. W12T Cell Transfected with siRNA
Purified siRNA against HPV16 E6 (51GUUACCACAGUUAUGCACATT31) or a control siRNA
(siGLO), were transfected into 1.5 ˆ 105 W12T cells per well in DMEM with 10% FCS using
Lipofectamine RNAiMAX (Invitrogen, Paisley, UK) according to the manufacturer’s instructions. The
final siRNA final concentration was 0.2 µM. Cells were harvested for analysis at 32 h post-transfection.
2.7. Immunofluorescence Microscopy
Cell were grown on sterile 18 ˆ 18 mm coverslips until 90% confluent, washed three times
with PBS and fixed and permeabilised with 100% ice-cold methanol for 5 min at ´20 ˝C or with
58 mM sucrose, 4% formaldehyde in PBS for 10 min at room temperature [23]. Coverslips were
blocked using 5% (v/v) horse serum in PBS for 30 min at room temperature then washed three
times with PBS. Cells were incubated with diluted primary antibodies in 1% horse serum in PBS
for 1 h at room temperature. Coverslips were washed in PBS six times before incubation for 1 h with
secondary antibodies labelled with fluorescein or Texas-Red diluted 1:100 in PBS (Vector laboratories,
Peterborough, UK). After washing in PBS six times, the coverslips were mounted with Vectashield
mounting medium (with DAPI as a nuclear stain). Negative controls (no primary antibody) were
included in all experiments. Images were taken using a Zeiss LSM510 Meta confocal microscope.
3. Results
3.1. hDlg and Cx43 Interact In Vivo
Previously we demonstrated loss of GJIC in a number of HPV16-positive (CaSki, SiHa, W12T
(formerly named W12GPXY)) and HPV18-positive (HeLa) cervical cancer cell lines but not in
HPV16-positive non-tumour cervical epithelial cells (W12E, W12G) [23,24]. In the W12T cervical
tumour cells Cx43 was no longer located in membrane gap junction plaques but was redistributed
to the cytoplasm where it colocalised with the PDZ domain protein hDlg. Cx43 was also located
in the cytoplasm in two other HPV-16-positive cervical cancer cell lines (CaSki and SiHa cells
(Supplementary Figure S2). To determine if the Cx43/hDlg interaction occurs in cervical epithelial
tissues in vivo we examined location of the proteins in HPV16-positive high grade cervical lesions.
Analysis by immunofluorescence showed that hDlg and Cx43 co-localise in epithelial cells in discrete
regions of the cells i.e., perinuclear location (Figure 1A,B). To further define this, we probed tissues
using a proximity ligation assay (PLA), which identifies protein interactions based on proteins being
within 40 nm of each other. Figure 1C,D (red spots) shows detection of the hDlg-Cx43 complex
within the epithelial cells of the cervical lesion. Figure 1E shows low level detection of Cx43/hDlg
complexes in a limited area of a representative cervical tumour in agreement with the observation
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that Cx43 levels decline in cervical cancer tissues in vitro and in vivo [24,28,29]. Two cervical lesions
and two cervical cancers were examined and there was evidence that Cx43 and hDlg were in close
proximity in all tissues. Figure 1F shows a duolink secondary control. The image is from the outer
region of the tissue shown in Figure 1C. We chose this area of the tissue because it represents the
only autofluorescence we detected in any of the tissues we examined. Some antibody trapping on
the outer surface of the epithelium was detected but there was no staining detected in the cells in
the tissue interior. These data confirm our previous in vitro findings that Cx43 and hDlg interact and
demonstrates the formation of protein complexes in human cervical epithelial cells in vivo.
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Figure 1. Cx43 and hDlg interact directly in cervical tumour cells in vivo. (A) Representative 
immunofluorescence image showing a section of a high grade cervical lesion; (B) A region of Cx43 
and hDlg colocalisation in (A) enlarged 5×. Immunofluorescence shows hDlg (green), Cx43 (red)  
and DAPI (blue). The yellow arrow indicates one area of Cx43/hDlg colocalisation; (C) 
Immunofluorescence proximity ligation for hDlg and Cx43, where red staining indicates 
colocalisation of the proteins within 40 nm of each other; (D) Regions of Cx43 and hDlg colocalisation 
detected by PLA in C enlarged 5×; (E) Immunofluorescence proximity ligation for hDlg and Cx43 in 
a region of a cervical tumour; (F) Immunofluorescence proximity ligation secondary control on the 
outer region of the cervical lesion a part of which is shown in (C). 
3.2. HPV16 E6 Is Present in a Complex Containing hDlg and Cx43 Cervical Tumour Cells 
Structural analysis has demonstrated that PDZ domains in hDlg can bind to the X-S/T-X-V/L 
protein motif of high risk HPV E6 proteins [14]. As we have shown previously that the C-terminal 
domain of Cx43 interacts with the N- and C- termini of hDlg [23], it is possible that E6, a 17 kDa 
protein, could form a complex with hDlg while hDlg is also bound to Cx43. Therefore we investigated 
formation of protein complexes between Cx43, hDlg and E6 by co-immunoprecipitation in W12G 
(non-tumour cervical epithelial cells) and in W12T (cervical tumour) cells (Figure 2). 
Cx43 and hDlg were co-immunoprecipitated from both W12G (top panel, lane 3) and W12T  
(top panel, lane 5) cell extracts (Figure 2A). Moreover, as expected, E6/hDlg complexes were able to 
be precipitated from both W12G and W12T cells (Figure 2A middle panel, lanes 3 and 5) but were 
more abundant in the latter. Co-immunoprecipitation of Cx43 with E6 antibody was detected at low 
levels in W12T cells (Figure 2A, bottom panel, lane 5) but not in W12G cells. A reverse precipitation 
Figure 1. Cx43 and hDlg interact directly i i l tumour cells in ivo. (A) Representative
immunofluorescence image showing a section of a high grade cervical lesion; (B) A region of
Cx43 and hDlg colocalisation in (A) enlarged 5ˆ. Immunofluorescence shows hDlg (green),
Cx43 (red) and DAPI (blue). The yellow arrow indicates one area of Cx43/hDlg colocalisation;
(C) Immunofluorescence proximity ligation for hDlg and Cx43, where red staining indicates
colocalisation of the proteins within 40 nm of each other; (D) Regions of Cx43 and hDlg colocalisation
detected by PLA in C enlarged 5ˆ; (E) Immunofluorescence proximity ligation for hDlg and Cx43 in
a region of a cervical tumour; (F) Immunofluorescence proximity ligation secondary control on the
outer region of the cervical lesion a part of which is shown in (C).
3.2. HPV16 E6 Is Present in a Complex Containing hDlg and Cx43 Cervical Tumour Cells
Structural analysis has demonstrated that PDZ domains in hDlg can bind to the X-S/T-X-V/L
protein motif of high risk HPV E6 proteins [14]. As we have shown previously that the C-terminal
domain of Cx43 interacts with the N- and C- termini of hDlg [23], it is possible that E6, a 17 kDa
protein, could form a complex with hDlg while hDlg is also bound to Cx43. Therefore we investigated
formation of protein complexes between Cx43, hDlg and E6 by co-immunoprecipitation in W12G
(non-tumour cervical epithelial cells) and in W12T (cervical tumour) cells (Figure 2).
Cx43 and hDlg were co-immunoprecipitated from both W12G (top panel, lane 3) and W12T
(top panel, lane 5) cell extracts (Figure 2A). Moreover, as expected, E6/hDlg compl xes were able to
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be precipitated from both W12G and W12T cells (Figure 2A middle panel, lanes 3 and 5) but were
more abundant in the latter. Co-immunoprecipitation of Cx43 with E6 antibody was detected at low
levels in W12T cells (Figure 2A, bottom panel, lane 5) but not in W12G cells. A reverse precipitation of
E6 with hDlg or Cx43 was not successful due to poor reactivity of the HPV16 E6 antibody in western
blots. These data indicate that in cervical tumour cells E6 can be part of a complex containing hDlg
and Cx43, at least at low levels.
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Figure 2. HPV16 E6 associates with Cx43 in W12T cervical cancer cells. (A) Co-immunoprecipitation 
of E6 with hDlg and Cx43 in W12G non-tumour and W12T tumour cells. Antibodies used in 
immunoprecipitation (IP) and the antibodies used to probe western blots (WB) are indicated on the 
right hand side. No IgG, beads alone used in the immunoprecipitation. Cntr IgG, a matched antibody 
isotype negative control immunoprecipitation. Input, 10% of the volume of cellular extract as used in 
the co-immunoprecipitation experiments; (B) Confocal immunofluorescence microscopy imaging 
showing E6 (green) in the nucleus of W12G cells (arrowheads) but in the cytoplasm of W12T cells 
(arrows); (C) Confocal immunofluorescence microscopy imaging of Cx43 (red) in W12G cells located 
in large punctuate gap junction plaques (arrowheads) on the membrane. In W12T cells membrane 
Cx43 (red) is reduced and some perinuclear staining is detected (arrows). E6 is shown in green. Nuclei 
are stained with DAPI (blue). Bar = 10 μM. 
Next we used confocal immunofluorescence microscopy to investigate the subcellular location 
of endogenous Cx43 and E6 in the W12 non-tumour and tumour cells. In the W12G non-tumour cells 
E6 was primarily localised within the nucleus as expected (Figure 2B, arrowheads) [30]. However, in 
the W12T tumour cells E6 was located in both the nucleus and the cytoplasm (Figure 2B, arrows). 
Immunofluorescence analysis of E6 and Cx43 in the two cell types revealed that Cx43 was located 
mainly in gap junction plaques (arrowheads) at the plasma membrane in W12G cells. There was no 
colocalisation of E6 and Cx43 as they were detected in different subcellular compartments (Figure 
2C). However, in W12T cells Cx43 was located in a perinuclear location in the cytoplasm as 
previously observed (arrows) [23,24] and E6 was diffusely located in the cytoplasm (Figure 2C). E6 
and Cx43 colocalised around the nucleus of W12T cells 
3.3. HPV16 E6 Controls Cx43 Trafficking in Cervical Tumour Cells 
Since our previous study indicated that hDlg was not responsible for Cx43 relocation from the 
membrane to the cytoplasm [23] next, we investigated the hypothesis that if E6 can potentially form 
a complex with hDlg and Cx43 it could restrict Cx43 trafficking to the plasma membrane. W12G and 
W12T are isogenic cell lines where the HPV16 genome is integrated into the host genome. Both lines 
express only the bicistronic E6E7 viral mRNA [25,31]. Therefore, we depleted the E6E7 mRNA using 
siRNA and examined changes in the subcellular location of Cx43 in W12T cells. Western blotting 
showed that specific siRNA treatment caused a marked reduction in total E6 protein levels (Figure 
3A). Confocal immunofluorescence microscopy showed that treatment of W12T cells with a control 
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of E6 with hDlg and Cx43 in W12G non-tumour and W12T tumour cells. Antibodies used in
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showing E6 (green) in the nucleus of W12G cells (arrowheads) but in the cytoplasm of W12T cells
(arrows); (C) Confocal immunofluorescence microscopy imaging of Cx43 (red) in W12G cells located
in large punctuate gap junction plaques (arrowheads) on the membrane. In W12T cells membrane
Cx43 (red) is reduced and some perinuclear staining is detected (arrows). E6 is shown in green. Nuclei
are stained with DAPI (blue). Bar = 10 µM.
Next we used confocal immu ofluorescence microscopy to investigate the subcellular location
of endogenous Cx43 and E6 in the W12 non-tumour and tumour cells. In the W12G non-tumour cells
E6 was primarily localised within the nucleus as expected (Figure 2B, arrowheads) [30]. However,
in the W12T tumour cells E6 was located in both the nucleus and the cytoplasm (Figure 2B, arrows).
Immunofluorescence analysis of E6 and Cx43 in the two cell types revealed that Cx43 was located
mainly in gap junction plaques (arrowheads) at the plasma membrane in W12G cells. There was no
coloc lisation of E6 and Cx43 as t y were detected in different subcellular compartments (Figure 2C).
However, in W12T cells Cx43 was located in a perinuclear location in the cytoplasm as previously
observed (arrows) [23,24] and E6 was diffusely located in the cytoplasm (Figure 2C). E6 and Cx43
colocalised around the n cle s of W12T cells
3.3. HPV16 E6 Controls Cx43 Trafficking in Cervical Tumour Cells
Since our previous study indicated that hDlg was not responsible for Cx43 relocation from the
membrane to the cytoplasm [23] next, we investigated the hypothesis that if E6 can potentially form
a complex with hDlg and Cx43 it could restrict Cx43 trafficking to the plasma membrane. W12G
and W12T are isogenic cell lines where the HPV16 genome is integrated into the host genome. Both
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lines express only the bicistronic E6E7 viral mRNA [25,31]. Therefore, we depleted the E6E7 mRNA
using siRNA and examined changes in the subcellular location of Cx43 in W12T cells. Western
blotting showed that specific siRNA treatment caused a marked reduction in total E6 protein levels
(Figure 3A). Confocal immunofluorescence microscopy showed that treatment of W12T cells with a
control siRNA (siGLO) did not alter the cytoplasmic location of Cx43 (Figure 3B arrowheads). In
contrast, treatment of W12T cells with the E6 siRNA resulted in some restoration of Cx43 on the
plasma membrane in typical gap junction plaques at points of cell-cell contact (Figure 3C, arrows).
hDlg also appeared at the membrane in the E6 siRNA-treated cells (Figure 3C). These data indicate
that a protein translated from the E6E7 bicistronic mRNA may be involved in Cx43 (and hDlg)
intracellular trafficking. There are a number of possible proteins: E6 full length, E6*I, E6*II, E6*X
and E7 [32]. However, only E6 full length can bind hDlg. Next we tested whether this protein was
responsible for controlling Cx43.
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Figure 3. E6 restricts Cx43 trafficking to the plasma membrane in W12T cells. (A) Western blot 
showing depletion of E6 following siRNA treatment of W12T cells. Lipo, mock transfected cells 
treated with lipofectamine. siGLO, cells transfected with control siRNA. E6 siRNA, cells transfected 
with HPV16 E6 siRNA; (B) Confocal immunofluorescence microscopy imaging showing the location 
of hDlg (red) and Cx43 (green) in control transfected W12T cells or in W12T cells transfected with 
siRNA against E6. Arrowheads indicate cytoplasmic Cx43 while arrows indicate Cx43 located in gap 
junctions plaques on the cell membrane. Nuclei are stained with DAPI. Bar = 10 μM. 
3.4. HPV E6 Causes Reduced Levels of Cx43 in C33a Cells 
Previously we found that cytoplasmic hDlg protected a pool of Cx43 from degradation: siRNA 
depletion of hDlg resulted in reduced levels of Cx43 in W12T cells [23]. Although not as efficient as 
HPV18 E6, HPV16 E6 can target hDlg for degradation via the proteasome in cervical cancer cells [27]. 
Thus it is possible that the reduction in Cx43 levels following depletion of hDlg could be mediated 
by HPV E6. To test this we examined Cx43 expression in HPV-negative C33a cervical tumour cells 
stably transfected with either an empty FLAG vector (C33aV, no E6 expression) or a vector expressing 
FLAG-tagged HPV16 E6 (C33a16E6). Levels of Cx43 protein were assessed using a protein lysate 
titration western blot and quantified (Figure 4A,B). As expected FLAG-E6 was detected using an anti-
FLAG antibody in C33a16E6 cells but not in C33aV cells (Figure 4A). Expression of E6 in C33a16E6 
cells resulted in a significant reduction in Cx43 expression (Figure 4A,B) with no notable changes in 
the expression of hDlg (Figure 4A). These data suggest that E6 may target Cx43 for degradation 
independent of its effects on hDlg. 
C33a cells normally retain strong GJIC and display Cx43 gap junction plaques on the plasma 
membrane [24] indicating that HPV expression might regulate GJIC in tumour cells. To confirm our 
data that E6 regulates Cx43 intracellular trafficking we examined the effect of E6 expression on Cx43 
and hDlg in C33a cells using confocal immunofluorescence microscopy. Figure 4C (arrowheads) 
shows that Cx43 was located primarily on the plasma membranes between adjacent C33aV cells. In 
contrast, in C33a16E6 cells Cx43 was primarily localised within intracellular regions (Figure 4C 
arrows), with a marked reduction in membrane gap junction plaques. Figure 4D show that in these 
Figure 3. E6 restricts Cx43 trafficking to the plasma membrane in W12T cells. (A) Western blot
showing depletion of E6 following siRNA treatment of W12T cells. Lipo, mock transfected cells
treated with lipofectamine. siGLO, cells transfected with control siRNA. E6 siRNA, cells transfected
with HPV16 E6 siRNA; (B) Confocal immunofluorescence micr scopy imaging showing the location
of hDlg (red) and Cx43 (green) in control transfected W12T cells or in W12T cells transfected with
siRNA against E6. Arrowheads indicate cytoplasmic Cx43 while arrows indicate Cx43 located in gap
junctions plaques on the cell membrane. Nuclei are stained with DAPI. Bar = 10 µM.
3.4. HPV E6 Causes Reduced Levels of Cx43 in C33a Cells
Previously we found that cytoplasmic hDlg protected a pool of Cx43 from degradation: siRNA
depletion of hDlg resulted in reduced levels of Cx43 in W12T cells [23]. Although not as efficient
as HPV18 E6, HPV16 E6 can targ t hDlg for degrad tion via the prote some in cervical cancer
cells [27]. Thus it is possible that the reduction in Cx43 levels following depletion of hDlg could
be mediated by HPV E6. To test this we examined Cx43 expression in HPV-negative C33a cervical
tumour cells stably transfected with either an empty FLAG vector (C33aV, no E6 expression) or a
vector expr ssing FLAG-tagged HPV16 E6 (C33 16E6). Levels of Cx43 protein were ssessed using a
protein lysate titration western blot and quantified (Figure 4A,B). As expected FLAG-E6 was detected
using an anti-FLAG antibody in C33a16E6 cells but not in C33aV cells (Figure 4A). Expression of
E6 in C33a16E6 cells resulted in a significant reduction in Cx43 expression (Figure 4A,B) with no
notable changes in the expression of hDlg (Figure 4A). These data suggest that E6 may target Cx43
for degradation independent of its effects on hDlg.
C33a cells normally retain strong GJIC and display Cx43 gap junction plaques on the plasma
membrane [24] indicating that HPV expression might regulate GJIC in tumour cells. To confirm our
data that E6 regulates Cx43 intracellular trafficking we examined the effect of E6 expression on Cx43
and hDlg in C33a cells using confocal immunofluorescence microscopy. Figure 4C (arrowheads)
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shows that Cx43 was located primarily on the plasma membranes between adjacent C33aV
cells. In contrast, in C33a16E6 cells Cx43 was primarily localised within intracellular regions
(Figure 4C arrows), with a marked reduction in membrane gap junction plaques. Figure 4D show
that in these cells E6 was located throughout the cytoplasm and the nucleus with some evidence of
colocalisation with Cx43 on the plasma membrane (arrowhead) and in the cytoplasm (arrow). In
contrast to what we observed in W12T cells, hDlg was found mainly at the cell periphery and there
was only limited colocalisation of hDlg with Cx43 in the cytoplasm of C33a16E6 cells (Figure 4E).
To test the effect of ectopic expression of HPV16 E6 on Cx43 levels in a non-cervical tumour cell line
we transfected the FLAGE6 expression vector into HEK-293 cells. Figure 4F shows that no change
in hDlg levels was detected when E6 was expressed and instead of a decrease in Cx43 levels a slight
increase was observed. E6 expression did not cause Cx43 relocation from the membrane in these cells
(Figure 4G).
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experiments. The data show the mean and standard error of the mean; (C) Confocal 
immunofluorescence microscopy imaging of Cx43 (red) location in C33aV and C33a16E6 cells;  
(D) Confocal immunofluorescence microscopy imaging of the location of Cx43 (red) and E6 (green) 
in C33a16E6 cells. Cytoplasmic colocalisation is indicated (arrow). The arrowhead indicates some 
Cx43 remaining on the plasma membrane where there is also co-staining with E6; (E) Location of Cx43 
(red) and hDlg (green) in C33a16E6 cells. Co-staining in the cytoplasm is indicated with arrowheads. 
Nuclei are stained with DAPI. Bar = 10 μM; (F) Western blot analysis of Cx43 and hDlg levels in HEK-
293 cells expressing HPV16 E6. Mock, mock transfected cells, cntrl, cells transfected with a control 
plasmid, 16E6, cells transfected with an expression construct for HPV16 E6. (G) Confocal microscopy 
analysis of Cx43 location in 293 cells transfected with the control plasmid (mock) or with an 
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Figure 4. C33a cells expressing HPV16E6 show reduced Cx43 levels and some colocalisation between
E6 and Cx43 is seen in the cytoplasm. (A) Titration estern blot showing the l vels of Cx43
and hDlg in C33a cells stably transfected with vector alone (C33aV) or with a vector expressing
FLAG-tagged HPV16 E6 (C33a16E6). As indicated, 10, 5 or 2 µg protein extract was applied to
the lanes as indicated. hDlg degradation results in a product that appears as an additional protein
species of around 70 kDa (asterisk). E6 was detected in C33a16E6 cells using a FLAG antibody.
GAPDH is shown as a loading control; (B) Quantification of levels of Cx43 relative to GAPDH
from 5 separate western blot experiments. The data show the mean and standard error of the
mean; (C) Confocal immunofluorescence microscopy imaging of Cx43 (red) location in C33aV and
C33a16E6 c lls; (D) Confocal immunofluorescence microsc y imaging of the location of Cx43 (red)
and E6 (green) in C33a16E6 cells. Cytoplasmic colocalisation is indicated (arrow). The arrowhead
indicates some Cx43 remaining on the plasma membrane where there is also co-staining with E6;
(E) Location of Cx43 (red) and hDlg (green) in C33a16E6 cells. Co-staining in the cytoplasm is
indicated with arrowheads. Nuclei are stained with DAPI. Bar = 10 µM; (F) Western blot analysis of
Cx43 and hDlg levels in HEK-293 cells expressing HPV16 E6. Mock, mock transfected cells, cntrl, cells
transfected with a control plasmid, 16E6, cells transfected with an expression construct for HPV16 E6.
(G) Confocal microscopy analysis of Cx43 location in 293 cells transfected with the control plasmid
(mock) or with an expression construct for HPV16 E6 (16E6).
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3.5. E6 PDZ Binding Motif Is Required for Relocation of Cx43 from the Membrane to the Cytoplasm
To investigate the relationship between E6 and hDlg and Cx43 re-location to the cytoplasm in
cervical tumour cells, C33a cells were transfected with empty vector (C33aV) or a vector expressing
wild type E6 (C33a18E6) or the same vector expressing an HPV18 E6 mutant that does not bind
hDlg [27] (Figure 5A). This time HPV18 E6 was used because it binds and degrades hDlg more
effectively than HPV16 E6 [33]. Moreover, there is a high degree of conservation between the HPV18
and HPV16 E6 proteins and loss of Cx43 GJIC is observed in HPV18 as well as HPV16-positive
cervical tumour cells [24]. HPV18 E6 expression caused a reduction in both Cx43 and hDlg levels
but expression of the HPV18 E6 mutant that does not bind hDlg did not affect levels of either protein
compared to cells transfected with vector alone (Figure 5B). Similar to what was observed for HPV16
E6, Cx43 relocated from the cell membrane of C33aV cells (Figure 5C) to a perinuclear location in
the C33a cells expressing ectopic 18E6 (Figure 5C). hDlg was present at the membrane and in the
cytoplasm of both the C33aV and C33a18E6 cells but displayed increased colocalisation with Cx43 in
the C33a cells expressing 18E6 (Figure 5C).
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Our data suggest that E6 is involved in Cx43 trafficking and turnover in cervical cancer cells.  
E6 could control Cx43 via changes in intracellular signalling that impact on the Cx43 cytoplasmic  
C-terminal domain. Alternatively, E6 could regulate Cx43 via its effects on hDlg. If hDlg-E6 
interaction was important in Cx43 recycling from the membrane then a mutant E6 that could no 
longer bind hDlg might alter Cx43 trafficking. To test this, we examined the effects on Cx43 
localisation in C33a cells of the HPV18 E6 mutated in its hDlg binding motif (C33amut18E6) [27] 
(Figure 5C). In contrast to wild type E6 transfected cells (C33a18E6 cells) where Cx43 and hDlg were 
located in the cytoplasm and Cx43 was found in a perinuclear location (Figure 5C), C33a cells 
Figure 5. C33a cells expressing a mutant HPV18 E6 that cannot bind hDlg display membrane Cx43.
(A) Western blot analysis of FLAG E6 expression in C33a cells stably transfected with vector alone
(C33aV), vector expressing HPV18E6 (wt18E6) or a mutant HPV18 E6 that does not bind hDlg
(mut18E6); (B) Western blot analysis of levels of Cx43 and hDlg in C33aV, C33a wt18E6 and C33a
mut18E6. GAPDH is used as a loading control for the blots in (A,B); (C) Confocal immunofluorescence
microscopy imaging of Cx43 (green) and hDlg (red) in C33aV cells, C33a18E6 cells and C33amut18E6
cells (cells expressing C-terminal mutated 18E6 that cannot bind hDlg). Membrane gap junction
plaques are indicated with arrowheads. The arrow in B indicates cytoplasmic Cx43 staining. Nuclei
are stained with DAPI. Bar = 10 µM.
Our data suggest that E6 is involved in Cx43 trafficking and turnover in cervical cancer cells.
E6 could control Cx43 via changes in intracellular signalling that impact on the Cx43 cytoplasmic
C-terminal domain. Alternatively, E6 could regulate Cx43 via its effects on hDlg. If hDlg-E6
interaction was important in Cx43 recycling from the membrane then a mutant E6 that could no
longer bind hDlg might alter Cx43 trafficking. To test this, we examined the effects on Cx43
localisation in C33a cells of the HPV18 E6 mutated in its hDlg binding motif (C33amut18E6) [27]
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(Figure 5C). In contrast to wild type E6 transfected cells (C33a18E6 cells) where Cx43 and hDlg
were located in the cytoplasm and Cx43 was found in a perinuclear location (Figure 5C), C33a cells
expressing the mutant E6 displayed some Cx43 on the cell membrane in gap junction plaques. Taken
together these data reveal that high risk HPV E6 controls critical steps in Cx43 recycling from the
plasma membrane and, at least for HPV18, that E6 interaction with hDlg may underlie the loss of
GJIC observed in cervical tumour cells.
4. Discussion
Elucidation of the control of Cx43 trafficking is crucial in understanding gap junction and
connexin hemichannel assembly and disassembly, and its impact in a range of skin diseases,
cardiovascular disease, diabetes and cancer. Although both reduced levels and overexpression of
Cx43 have been reported in various cancers [7], loss of Cx43 from the plasma membrane has been
observed in cervical precancers and cancers [8]. These studies suggest that Cx43 trafficking is altered
in cervical cancer cells.
Previous studies on Cx43 trafficking have focused on the interaction of Cx43 with the
membrane-associated scaffolding protein ZO-1. ZO-1 was shown to control cell migration, adhesion
and Cx43 trafficking to and from the membrane in a range of cell types [34–39]. However, we
discovered that Cx43 interacts with another scaffolding protein hDlg, in HPV16-positive cervical
tumour cells. We have now confirmed this interaction can occur in vivo suggesting it has a functional
significance. hDlg appears to have a role in Cx43 trafficking by maintaining a cytoplasmic pool of
Cx43 protected from lysosomal degradation [23].
GJIC is disrupted and Cx43 is located in the cytoplasm of HPV-positive cervical tumour cells
but not in HPV-negative cervical tumour cells [24]. This indicates that one of the viral oncoproteins
could control Cx43 trafficking. High risk HPV E6 oncoprotein is the most obvious candidate because
it associates with hDlg through its C-terminal PDZ binding motif [14,15], and we have evidence that
Cx43 forms a complex with hDlg [23]. Because the amounts and intracellular locations of HPV16 E6
were significantly different between W12G non-tumour and the W12T tumour cells we considered
the hypothesis that cytoplasmic E6 in W12T cells could modulate Cx43 and/or hDlg trafficking to the
plasma membrane. Our data suggest that E6 does not appear to have a very strong interaction with
Cx43 because it was detected only at low levels in co-immunoprecipitation in cervical tumour cells.
This result is perhaps not surprising given that HPV16 E6 has been shown to interact with hDlg only
at low affinity [40]. Some co-localisation of E6 with Cx43 was detected in the cytoplasm of W12T and
in C33a cells ectopically expressing FLAG-tagged E6, but because E6 was distributed widely in the
cytoplasm the specificity of this co-localisation requires further investigation. The data suggest that
Cx43, hDlg and E6 interact in HPV-positive cervical tumour cells. It seems likely that Cx43 interaction
with E6 is mediated by E6 binding hDlg.
siRNA depletion of E6 in W12T cells led to relocation of some Cx43 onto the plasma membrane
where it formed gap junction plaques. This suggests that E6 is involved in the trafficking of Cx43. E6
can control intracellular signalling pathways [41–43] that impact upon Cx43 trafficking [6]. Therefore,
increased E6 levels could affect Cx43 trafficking indirectly via changes in intracellular signalling
sensed by the C-terminal intracellular domain of Cx43. Such changes may include post-translation
modifications such as phosphorylation. Indeed dephosphorylation of Cx43 is known to lead to loss
of Cx43 from gap junction plaques and intracellular relocation [44–46] and phosphorylation levels of
Cx43 are lower in W12T cells than in W12G cells (Supplementary Figure S1). Alternatively, formation
of an intracellular Cx43/hDlg/E6 complex in the E6-expressing cervical tumour cells might inhibit
Cx43 trafficking to the membrane directly by removing Cx43 from its normal trafficking pathway. In
our experiments HPV18 E6/hDlg interaction seemed to be important for Cx43 trafficking because it
was found on the plasma membrane in HPV-negative C33a cells expressing the hDlg binding mutant
of HPV18 E6 Cx43. It is also possible that hDlg could function in the transport cycle of Cx43 by
providing a docking platform for molecules [47] in addition to E6 that are involved in assembling or
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disassembling connexon hemichannels. Expression or activity of such molecules could be induced by
increased expression of E6 and/or by other changes induced by tumour progression.
It has been suggested that changes in Cx43 phosphorylation can be induced by changes in
tissue architecture [48]. Compared to W12G cells, W12T cells exhibit alterations in microtubules
and microfilaments and drug-induced disruption of the cytoskeleton led to changes in Cx43 cellular
location (unpublished data). Interestingly, no relocation of Cx43 was observed in HEK-293 cells
expressing HPV16 E6. It is possible that Cx43 post-translation modifications in HEK-293 cells result
in a protein that is not able to dock with hDlg (or other trafficking proteins) or that signalling
pathways in HEK-293 cells cannot be altered by E6 in a manner similar to those in W12T or C33a
cells. It will be interesting to examine Cx43 and hDlg localization in the normal cervix and the
HPV-infected cervix. For example, the transformation zone that has altered architecture and appears
to be susceptible to HPV infection may exhibit Cx43/hDlg colocalisation. The relative contribution of
E6/hDlg interaction, Cx43 phosphorylation and cytoskeletal alterations to Cx43 trafficking remains
to be tested in normal and tumour tissues.
Ectopic expression of E6 in C33a cervical tumour cells resulted in reduced levels of Cx43. These
data suggest that E6 is involved in targeting Cx43 for degradation. This observation correlates
with the fact that in W12T cells that express higher levels of E6, but not in the W12G cells that
express lower levels, Cx43 entered, and was degraded by, the lysosomal degradation pathway [23].
A study using clones of HPV-18 positive HeLa cervical tumour cells revealed a spectrum of Cx43
expression with the majority displaying no or low Cx43 levels in agreement with our data [28].
Similarly, in C33a cells expressing HPV18 E6 Cx43 was located in the cytoplasm and few gap junction
plaques were observed. In contrast, King et al. showed that overexpression of Cx43 in HeLa
cells resulted in appearance of gap junction plaques on the membrane [29]. However, Cx43 was
also strongly expressed in the nucleus and cytoplasm, presumably due to the very high levels of
Cx43 overexpression [29]. In this case endogenous HPV18 E6 could not mediate full cytoplasmic
internalization of Cx43 perhaps due to the large amount of Cx43 in the cell overwhelming trafficking
pathways. In HEK-293 cells overexpression of HPV16 E6 did not cause a reduction in Cx43 levels.
This suggests that the effect of E6 is cell type-specific and perhaps restricted to cancer cells, for
example Cx43 is also not degraded in W12G cells [23]. We have not yet tested whether Cx43 is
targeted for lysosomal degradation in C33aE6 cells. Critically, Cx43 can also be degraded by the
proteasome. E6 targets p53 for proteasomal degradation via the ubiquitin ligase, E6-associated
protein (E6AP). It is possible that via E6, E6AP may also be able to ubiquitinate Cx43 and target it
for degradation.
5. Conclusions
In conclusion, our findings highlight a role for high risk HPV E6 in Cx43 trafficking between
the plasma membrane and the cytoplasm. Taken together, the present results suggest that when
expressed at high levels, for example in cervical cancer cells, high risk HPV E6 may regulate Cx43
trafficking, resulting in decreased delivery of connexon hemichannels to the plasma membrane and
inhibition of the formation of gap junctions. Alternatively, E6 could control rapid recycling of gap
junction Cx43 into the cytoplasm. Whichever route is correct, reduced gap junctional communication
may be another pathway by which E6 overexpression leads to tumour progression.
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